| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1/2 data readout example | Phase 1/2 | — | Subscribe to access the data. | Small Molecules | Oncology | ||
Phase 1/2 data readout example | Phase 1/2 | — | Subscribe to access the data. | Small Molecules | Oncology | ||
Phase 1/2 data readout example | Phase 1/2 | — | Subscribe to access the data. | Small Molecules | Oncology |
Recent Updates
Recently added Catalysts
C4 Therapeutics, Inc.$4.06
-0.19 (-4.43%)
C 40Pipeline Score Fair Value Biotech · Commercial
Market Cap
393.62 M
EPS
-1.18
P/E Ratio
-
Value Trade
8.10 M
SEC Financials
Q1 2026Dilution Risk
Revenue
6.15 M
R&D Expenses
24.61 M
Operating CF
-29.94 M
Total Assets
328.86 M
Total Liabilities
94.61 M
Equity
234.25 M
D/E Ratio
12,345
-0.28 %
Week
13.02 %
1 Month
69.52 %
3 Month
48.33 %
6 Month
-90.41 %
5 Year
-86.62 %
All Time
Cash Data
Cash Position
268.27 M
Monthly Burn
9.98 M
Runway
25.2 mo
Burn Trend
SEC Filing
May 12, 2026
Overview
Volume
2.58 M
52 Week Range
1.21 - 3.95
% held by Insiders
8.26 %
% held by Institutions
80.75 %
Enterprise Value
216.40 M
Total Shares
96.94 M
Short %
21.93 %
Float Shares
75.13 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for C4 Therapeutics, Inc.
268Total events
7Upcoming
29Tier-1 (high impact)
2020 – 2028Coverage
Upcoming catalysts 7
2027-H1
T2Trial Initiation
Initiation of additional Phase 1b trial of cemsidomide in combination with approved MM therapies
Event history 261
Jun 12, 2026
◆Poster PresentationcemsidomidePresentation
Poster presentation of updated Phase 1 data at EHA Congress
relapsed/refractory multiple myelomasource ↗
Jun 10, 2026
Jun 3, 2026
May 29, 2026
◆Poster PresentationcemsidomidePresentation
Trial-in-progress poster for MOMENTUM trial at ASCO 2026
relapsed/refractory multiple myelomasource ↗
May 26, 2026
May 12, 2026
▼Program DiscontinuationCFT8919DiscontinuedCorporate
Decision to not advance CFT8919 into next phase outside Greater China
EGFR mutated non-small cell lung cancersource ↗
Apr 9, 2026
▲Partnership / LicenseCorporate
C4 Therapeutics enters new collaboration with Roche to develop degrader-antibody conjugates (DACs) for two oncology targets, with option for third
oncologysource ↗
Q2 2026
◆Trial InitiationcemsidomideTrial
Phase 1b trial of cemsidomide + elranatamab initiation on track for Q2 2026
relapsed/refractory multiple myelomasource ↗
Q2 2026
◆Timing GuidancecemsidomidePresentation
Plans to evaluate cemsidomide in other combinations to be shared in mid-2026
multiple myelomasource ↗
Apr 2026
▲Partnership / LicenseCorporate
New collaboration agreement with Roche for degrader-antibody conjugates
cancersource ↗
Drug Pipeline Intelligence
C40
Pipeline Score $210M
Pipeline ValueFair Value
Valuation Signal2
Drugs Scored1.8x
rNPV / MCap Top 58%
Micro Cap (rank 384 of 911)
Percentile RankC4 Therapeutics, Inc. carries a moderate pipeline score (40/100), with $524M risk-adjusted pipeline value, led by cemsidomide in Multiple Myeloma (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| cemsidomide Small molecule | Multiple Myeloma | Phase 2 | NCT04756726 | 10% | $477M | ACTIVE NOT_RECRUITING | 324 | VERY_FAST | D (35) | Dec 31, 2026 | HIGH_RISK | MEDIUM May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
cemsidomide | relapsed/refractory multiple myeloma | Phase 1 | 2026-06-11 | overall response rate: 53%; median prior lines of therapy: 7; prior BCMA therapy: 75%; prior CAR T or TCE therapy: 75%; ORR at 75µg: 40%; ORR across all doses: 36% Read More | C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population Read More | |
cemsidomide | relapsed/refractory multiple myeloma | Phase 1 | 2026-06-11 | overall response rate: 53%; median prior lines of therapy: 7; prior BCMA therapy: 75%; prior CAR T or TCE therapy: 75%; ORR at 75µg: 40%; ORR across all doses: 36% Read More | C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population Read More | |
cemsidomide | relapsed/refractory multiple myeloma | Phase 1 | 2026-06-11 | overall response rate: 53%; median prior lines of therapy: 7; prior BCMA therapy: 75%; prior CAR T or TCE therapy: 75%; ORR at 75µg: 40%; ORR across all doses: 36% Read More | C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CCCC
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CCCC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CCCCC4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population
C4 Therapeutics presented promising Phase 1 data for cemsidomide at the EHA 2026 Congress, showing a 53% overall response rate among heavily pretreated multiple myeloma patients. The drug was well tolerated, with minimal adverse effects. The findings support cemsidomide's potential as a foundational therapy in treating relapsed/refractory multiple myeloma, with evidence of deepening responses over time.
Read more →CCCC▲ +5.5%on this news
C4 Therapeutics to Participate in Upcoming Conferences
C4 Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in several upcoming conferences, including the TD Cowen 7th Annual Oncology Innovation Summit and the Jefferies Global Healthcare Conference. These events will feature management in virtual fireside chats and 1x1 meetings, showcasing the company's commitment to advancing targeted protein degradation science. Live webcasts will be available on their website.
Read more →CCCC▼ -9.6%on this newsshared move
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
C4 Therapeutics announced the approval of a non-qualified stock option grant for 85,480 shares to a new employee, as part of an inducement to join the company. This grant, made under Nasdaq Listing Rule 5635(c)(4), will vest over four years, with a portion vesting annually. C4T focuses on advancing targeted protein degradation science to develop innovative medicines.
Read more →CCCCC4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
C4 Therapeutics reported its first quarter 2026 financial results, highlighting significant advancements in its clinical trials for cemsidomide, a potential treatment for multiple myeloma. The company initiated two new trials and expanded its collaboration with Roche. Despite a decrease in revenue, C4T maintains a strong financial position to support ongoing development.
Read more →CCCCC4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)
C4 Therapeutics has entered a new collaboration agreement with Roche to develop degrader-antibody conjugates (DACs) targeting two oncology indications. The partnership will leverage C4T's proprietary TORPEDO platform and Roche's expertise in antibody-drug conjugation. C4T will receive a $20 million upfront payment and could earn over $1 billion in milestone payments. This collaboration aims to enhance cancer treatment options.
Read more →CCCC▲ +7.6%on this news
C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma
C4 Therapeutics has announced the dosing of the first patient in its Phase 1b trial for cemsidomide, an oral IKZF1/3 degrader, in combination with elranatamab for treating relapsed/refractory multiple myeloma. The trial aims to evaluate the safety, tolerability, and preliminary efficacy of this combination therapy. C4T anticipates data from the trial by mid-2027, which is part of a broader strategy to support cemsidomide's use across multiple treatment lines.
Read more →CCCCC4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
C4 Therapeutics reported its financial results for 2025, highlighting advancements in its lead candidate, cemsidomide, which is progressing into later-stage clinical trials for multiple myeloma. The company also announced a strong cash position, enabling operations through 2028. Despite a significant net loss, the company remains optimistic about its drug development pipeline and potential market impact.
Read more →CCCC▲ +6.5%on this news· ran to +29% by day 3shared move
C4 Therapeutics to Participate in Upcoming March Conferences
C4 Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in two upcoming March conferences. The live webcasts will be accessible on the company's website, with archived replays available for 90 days post-event. C4T focuses on targeted protein degradation to develop new medicines aimed at difficult-to-treat diseases.
Read more →CCCC▲ +6.5%on this news· ran to +29% by day 3shared move
C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma
C4 Therapeutics has initiated the Phase 2 MOMENTUM trial, dosing the first patient with cemsidomide combined with dexamethasone for relapsed/refractory multiple myeloma. This trial aims to evaluate the drug's efficacy and safety, building on positive Phase 1 results. The company is also preparing for a Phase 1b trial with cemsidomide and elranatamab.
Read more →CCCCC4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - February 9, 2026
C4 Therapeutics announced the approval of a non-qualified stock option grant for 162,880 shares to a new employee, as part of an Inducement Grant under Nasdaq Listing Rule 5635(c)(4). This grant, effective February 9, 2026, will vest over four years, promoting long-term employment. C4T continues to advance its targeted protein degradation initiatives.
Read more →CCCC▼ -6%on this news
C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
C4 Therapeutics will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026, scheduled for February 11-12 in New York. The company's management will engage in a fireside chat, which will be available via live webcast. This event emphasizes C4T's commitment to advancing targeted protein degradation science.
Read more →CCCCC4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - January 26, 2026
C4 Therapeutics announced the approval of an Inducement Grant for a new employee, consisting of non-qualified stock options for 85,480 shares. This grant, made in accordance with Nasdaq Listing Rule 5635(c)(4), will vest over four years, incentivizing the new hire's continued employment. The exercise price is set at the closing stock price on the grant date.
Read more →CCCCC4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways
C4 Therapeutics has outlined strategic milestones aimed at advancing cemsidomide, an investigational drug for multiple myeloma, with trials set to initiate in 2026. The company is also focusing on novel targets in inflammation and neuro-degenerative diseases. Their financial stability extends through 2028, supporting ongoing development efforts.
Read more →CCCCC4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
C4 Therapeutics reported its Q3 2025 financial results, highlighting a successful equity offering that raised $125 million, extending its financial runway to 2028. The company is advancing its lead candidate, cemsidomide, which demonstrated a 53% overall response rate in Phase 1 trials for multiple myeloma. C4T plans to initiate the registrational Phase 2 MOMENTUM trial in early 2026.
Read more →CCCC▲ +11.7%on this news
C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering
C4 Therapeutics has announced a $125 million underwritten offering to fund the next phase of its cemsidomide development for multiple myeloma. This includes a registrational Phase 2 trial in combination with dexamethasone and a Phase 1b trial with elranatamab. The offering is expected to close on October 17, 2025, subject to customary conditions.
Read more →CCCCC4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma
C4 Therapeutics has announced a collaboration with Pfizer to conduct a Phase 1b trial evaluating the combination of cemsidomide and elranatamab for treating relapsed/refractory multiple myeloma. The trial, set to begin in Q2 2026, will assess safety and tolerability while establishing an optimal dosage. This partnership aims to enhance treatment options for patients.
Read more →CCCC▼ -17.4%on this news· ran to -31% by day 3
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting
C4 Therapeutics presented promising Phase 1 trial results for cemsidomide, an IKZF1/3 degrader, at the International Myeloma Society Annual Meeting. The drug demonstrated a 50% overall response rate at the highest dose and a favorable safety profile. C4T plans to initiate Phase 2 and Phase 1b studies in 2026 to further evaluate cemsidomide's efficacy and potential for accelerated approval.
Read more →CCCCC4 Therapeutics Highlights Recent Achievement in Biogen Collaboration
C4 Therapeutics announced that its partner Biogen has received FDA acceptance for the IND application of BIIB142, a degrader of IRAK4 aimed at treating autoimmune diseases. This milestone highlights the successful collaboration between the two companies, which began in 2018, and positions C4T to receive a $2 million milestone payment upon patient dosing in the clinical trial. The partnership aims to leverage targeted protein degradation to address unmet medical needs.
Read more →CCCCC4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting
C4 Therapeutics announced that it will present data from its Phase 1 trial of cemsidomide for multiple myeloma at the IMS Annual Meeting on September 20, 2025. The presentation will include safety and efficacy data from all evaluable patients in the trial. C4T's investor webcast will follow the presentation to discuss further clinical development plans.
Read more →CCCC▲ +9%on this news
C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights Cemsidomide Phase 1 Data in Multiple Myeloma Accepted as an Oral Presentation at the International Myeloma Society (IMS) Annual
C4 Therapeutics reported its financial results for Q2 2025, highlighting significant milestones in the development of Cemsidomide for multiple myeloma. The company's Phase 1 trial data, which results indicate a response rate between 40% and 50%, has been accepted for presentation at the upcoming International Myeloma Society Annual Meeting. C4T has engaged in productive discussions with the FDA regarding its development plans, projecting to start registrational studies in early 2026. However, the company also noted a decrease in total revenue and an increase in net loss compared to the same period in 2024.
Read more →CCCC▲ +6.4%on this news
C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights Updated Cemsidomide Multiple Myeloma Data Further Demonstrate Compelling Response Rates at Multiple Doses and Potential for Best
C4 Therapeutics (Nasdaq: CCCC) reported its financial results for Q1 2025, highlighting significant advancements with cemsidomide in treating multiple myeloma. The data revealed a compelling overall response rate of 50% at the highest dose level and indicated sustained safety and tolerability. C4T is prioritizing further development of cemsidomide and anticipates regulatory feedback by mid-2025 to facilitate next phase initiatives. The company reported a $234.7 million cash position, expected to support its operations into 2027.
Read more →CCCCC4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights Planning Activities Are Ongoing for Next Phase of Cemsidomide Clinical Development in Multiple Myeloma and Non-Ho
C4 Therapeutics, Inc. reported its financial results for the fourth quarter and full year of 2024, noting significant revenue growth to $35.6 million. The company remains focused on advancing its clinical development programs, particularly for cemsidomide in multiple myeloma and non-Hodgkin's lymphoma, with trials expected to begin in early 2026. Cash reserves of $267.3 million are anticipated to support operations through 2027. Despite continued high R&D expenses, the company is optimistic about the outcomes of its ongoing studies.
Read more →CCCCC4 Therapeutics to Participate in Upcoming March Investor Conferences
C4 Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in two investor conferences scheduled for March. The company focuses on targeted protein degradation to develop innovative medicines aimed at improving patient outcomes. C4T's approach utilizes its TORPEDO® platform to design small-molecule therapies for challenging diseases.
Read more →CCCC▲ +6.9%on this news
C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology Cemsidomide Data Presented at American Society of Hematology (ASH) Annual Meeting
C4 Therapeutics has announced its milestones for 2025, focusing on its clinical portfolio of degrader medicines targeting high unmet needs in oncology. The company highlighted advancements in its cemsidomide and CFT1946 trials, with key data presentations expected in the latter half of 2025. Additionally, C4T's cash runway is anticipated to support its operations until at least 2027. The company remains committed to leveraging its TORPEDO platform to develop therapies for difficult-to-treat cancers.
Read more →CCCC▼ -5.2%on this news
C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1 3 Degrader In Multiple Myeloma, Cemsidomide in Combi
C4 Therapeutics presented positive Phase 1 data for its drug, cemsidomide, at the ASH Annual Meeting, highlighting its potential as a best-in-class IKZF1 3 degrader for treating multiple myeloma and non-Hodgkin's lymphoma. The data revealed a 36% overall response rate in combination with dexamethasone for multiple myeloma and a 38% overall response rate as a monotherapy in non-Hodgkin's lymphoma. Cemsidomide exhibited a well-tolerated safety profile, with low rates of severe adverse events. The company aims to further investigate the drug's efficacy across various combination regimens.
Read more →CCCCC4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors Hoerter Brings Over Three Decades of Oncology Commercialization and Leadership Experience Appointment Underscores Continued Tra
C4 Therapeutics has appointed Steve Hoerter to its Board of Directors, enhancing its leadership team with over three decades of oncology commercialization experience. Hoerter's background includes significant roles in companies such as Deciphera Pharmaceuticals and Agios Pharmaceuticals, where he successfully launched key oncology products. His addition to the board is seen as a strategic move to guide C4T in advancing its pipeline of targeted protein degraders. The company aims to address significant unmet needs in cancer treatment with its innovative therapies.
Read more →CCCCC4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights Cemsidomide Phase 1 2 Trial in Multiple Myeloma and non-Hodgkin's Lymphoma Continues to Progress Data from Both Indications to b
C4 Therapeutics, Inc. announced its financial results for the third quarter of 2024, highlighting a revenue increase to $15.4 million, driven by collaboration milestones. The ongoing clinical trials for their drugs cemsidomide and CFT1946 are advancing well, with promising safety data and anticipated updates at upcoming medical conferences. The company maintains a strong financial position, with cash reserves expected to last into 2027. However, R&D and G&A expenses have risen, contributing to a net loss of $24.7 million for the quarter.
Read more →CCCC▲ +11.1%on this news
C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D. Mahaney Brings More Than 25 Years of Pharmaceutical and Biotech Experience Overseeing Drug Disc
C4 Therapeutics has appointed Paige Mahaney, Ph.D., as the new Chief Scientific Officer, effective October 28, 2024, following the retirement of Stewart Fisher, Ph.D. Fisher will continue to support the company as a senior scientific advisor through 2024. The new appointment is expected to leverage Mahaney's extensive drug discovery experience to advance targeted protein degradation science and further develop C4T's clinical portfolio. Fisher has significantly contributed to the company's progress in the targeted protein degradation field over the past years.
Read more →CCCCC4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors
C4 Therapeutics has appointed Stephen Fawell, Ph.D., to its Board of Directors as part of an ongoing evolution within the company. Fawell brings nearly 35 years of drug discovery experience, particularly in oncology, and will support the management team in advancing the company's targeted protein degradation programs. The appointment follows the retirement of Malcolm Salter, who was instrumental in C4T's development since its founding. C4 Therapeutics focuses on creating innovative medicines aimed at addressing difficult-to-treat diseases through its TORPEDO platform.
Read more →CCCCC4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights Preliminary Monotherapy Data from the Ongoing CFT1946 Phase 1 Trial in BRAF V600X Solid Tumors to be Presented at ESMO Congress
C4 Therapeutics reported its second quarter 2024 financial results, revealing a significant increase in revenue to $12 million due to a milestone payment from Biogen. The company is advancing its clinical trials, particularly for CFT1946, which targets BRAF V600X mutations, and is set to present preliminary data at the upcoming ESMO Congress. C4T's financial position remains strong, with $295.7 million in cash reserves expected to support operations through 2027. Net losses have decreased compared to the previous year, indicating improved financial management.
Read more →CCCCC4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors Cooper Brings Decades of Global Pharmaceutical and Biotechnology Leadership Experience Bruce Downey Remains a Member of the Board of Directors and
C4 Therapeutics has appointed Ron Cooper as the new Chairman of the Board of Directors, promoting strategic growth within the company. Cooper, who previously led Albireo Pharma, brings nearly 30 years of experience from Bristol-Myers Squibb. Bruce Downey will remain on the board but step down from the chairman role, as the company aims to strengthen its leadership and position itself as a fully integrated biotechnology firm focusing on targeted protein degradation. The company remains committed to advancing its pipeline and addressing complex diseases.
Read more →CCCC▼ -5%on this news
C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights Successfully Delivered First Development Candidate to Biogen $8 Million Payment Earned Established a Strategic Discovery Researc
C4 Therapeutics reported its first quarter 2024 financial results, showcasing several achievements including the successful delivery of its first development candidate to Biogen, which earned the company $8 million. Additionally, C4T established a collaboration agreement with Merck KGaA focused on developing targeted protein degraders. The company is advancing its Phase 1 clinical trials for Cemsidomide and CFT1946, with results anticipated later this year. As of March 31, 2024, C4T reported $299.2 million in cash, which is expected to fund operations into 2027.
Read more →CCCCC4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins Collaboration Focused on Two Targeted Protein Degraders from C4T's Internal Di
C4 Therapeutics has established a strategic collaboration with Merck KGaA to discover two targeted protein degraders aimed at critical oncogenic proteins. As part of the agreement, C4T will receive a $16 million upfront payment and could earn up to approximately $740 million in potential milestone payments. The collaboration will leverage C4T's TORPEDO platform for drug discovery, while Merck KGaA will handle clinical development and commercialization activities. This partnership emphasizes the commitment of both companies to improving cancer treatment outcomes.
Read more →CCCC▲ +21.4%on this news· ran to +34% by day 3
C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights CFT1946 Preclinical Data Accepted for a Poster Presentation at the AACR Annual Meeting 2024 Phase 1 Dose Escalati
C4 Therapeutics reported its financial results for 2023, highlighting key achievements in clinical trials and collaborations. The company noted positive data from its CFT7455 and CFT1946 programs while extending its cash runway into 2027. However, it also faced challenges, including a decrease in total revenue and an increase in net loss compared to the previous year. Looking ahead, C4T plans to present additional data from its trials in the second half of 2024.
Read more →CCCC▲ +98.3%on this news· ran to +367% by day 1
C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed Refractory Multiple Myeloma Data Support 14 Days On 14 Days Off as Optimal Dosing Schedule CFT7455 is Well Tolerated with Promising Signs of
C4 Therapeutics has announced encouraging results from its Phase 1 trial of CFT7455 for treating relapsed refractory multiple myeloma and non-Hodgkin's lymphomas. The data indicate that CFT7455 is well tolerated and exhibits anti-myeloma and immunomodulatory effects, particularly when administered with dexamethasone. The optimal dosing schedule of 14 days on, 14 days off has been established, aligning with preclinical findings. Further data presentations regarding CFT7455 are anticipated in 2024.
Read more →CCCC▲ +98.3%on this news· ran to +367% by day 1
C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs) Initial Focus on One Oncology Target, Exclusive to Collaboration Merck has Option for Th
C4 Therapeutics has announced a collaboration and licensing agreement with Merck to develop degrader-antibody conjugates (DACs) aimed at cancer treatment. The initial focus will be on a specific oncology target exclusive to this collaboration, with potential for further targets. Under the agreement, C4T will receive a $10 million upfront payment and the possibility of up to $2.5 billion in additional payments. This partnership combines C4T's expertise in targeted protein degradation with Merck's capabilities in antibody-drug conjugation.
Read more →CCCC▼ -6.6%on this news· ran to -18% by day 1
C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment Owen Hughes, Accomplished Life Sciences Executive with Deep Experience Across Investing, Operations and Governance, Appointed as Independent Mem
C4 Therapeutics has appointed Owen Hughes as an independent member of its board of directors. Hughes brings nearly three decades of experience in life sciences, with a proven track record in investing and corporate governance. His previous roles include leadership positions at Cullinan Oncology and Intarcia Therapeutics, where he raised significant capital for various projects. The company believes Hughes's expertise will enhance its strategic advancement of novel targeted protein degradation therapies.
Read more →CCCC▼ -11.4%on this news· ran to +21% by day 3
C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights Portfolio Decision to Prioritize Ongoing Phase 1 2 Trials of CFT7455, an IKZF1 3 Degrader, and CFT1946, a BRAF V600 Degrader CFT
C4 Therapeutics has reported its financial results for the third quarter of 2023, highlighting a revenue increase as well as progress in clinical trials for CFT7455 and CFT1946. However, the company has decided not to advance CFT8634 beyond Phase 1 due to insufficient efficacy in treating synovial sarcoma and SMARCB1-null tumors. Furthermore, challenges have arisen in collaboration with Betta Pharmaceuticals regarding a funding agreement. Overall, C4T maintains a strong cash position with expectations of sustained financial support into 2025.
Read more →CCCC▼ -7.3%on this news· ran to -20% by day 3
C4 Therapeutics Announces Chief Financial Officer Succession
C4 Therapeutics has announced Kendra Adams as the new Chief Financial Officer, effective September 18, 2023, succeeding Lauren White. Adams, who has over 25 years of experience, joined C4T in November 2020 and has a strong background in investor relations within the biotechnology sector. The company is optimistic about leveraging her expertise as it prepares for two clinical updates this year. CEO Andrew Hirsch indicated a commitment to advancing their pipeline of degrader medicines.
Read more →CCCCC4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights Established Exclusive Licensing Agreement for CFT8919, an EGFR L858R BiDAC Degrader, with Betta Pharmaceuticals in Greater Chin
C4 Therapeutics recently reported its second quarter 2023 financial results, highlighting key business achievements. The company secured an exclusive licensing agreement with Betta Pharmaceuticals for CFT8919, aiming to develop it in Greater China. Several clinical trials for its degrader therapies, including CFT7455 and CFT8634, are ongoing, with expected updates later in 2023. Financially, the company faced a revenue decline compared to the previous year, alongside increased net losses, but maintains a strong cash position to support future initiatives.
Read more →CCCC▼ -7.7%on this news
Document C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer
C4 Therapeutics has announced the appointment of Dr. Leonard Reyno as Chief Medical Officer, effective July 10, 2023. With nearly 30 years of clinical development experience, Dr. Reyno is expected to lead C4T's clinical strategy and oversee its pipeline of degrader therapies. Prior to this role, he held senior positions at Pionyr Immunotherapeutics and ORIC Pharmaceuticals, making significant contributions to oncology therapeutics. C4 Therapeutics aims to leverage its TORPEDO platform to enhance drug development and transform treatment options for diseases.
Read more →CCCCC4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights Preclinical Data Presented at AACR Demonstrated CFT1946 is a Potent and Mutant-Selective BRAF V600 BiDAC Degrader Phase 1 2 Clin
C4 Therapeutics reported its financial results for the first quarter of 2023, highlighting key advances in its clinical pipeline, including the CFT1946 BiDAC degrader, which is currently enrolling patients in a Phase 1/2 trial. Recent data presented at the AACR conference indicated CFT1946's efficacy against BRAF V600 mutations. The company also indicated continued spending on R&D, resulting in a larger net loss than the previous year, while maintaining a robust cash position projected to fund operations through 2025.
Read more →CCCCC4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights Phase 1 Dose Escalation Data from the Ongoing Phase 1 2 Clinical Trials of CFT7455, an IKZF1 3 MonoDAC Degrader,
C4 Therapeutics (ticker: CCCC) has announced its financial results for Q4 and the full year of 2022, highlighting progress in several clinical trials, including CFT7455 and CFT8634. The company reported a decrease in revenue due to previous one-time revenue recognitions and increased research and development expenses. Despite these challenges, C4T expressed optimism for 2023, with cash reserves expected to support operations and multiple clinical readouts anticipated in the second half of the year. Preclinical data on the drug candidate CFT1946 has also been accepted for presentation at the AACR Annual Meeting.
Read more →CCCC▲ +6.4%on this news· ran to +34% by day 3
Document C4 Therapeutics Announces 2023 Strategic Priorities to Advance Portfolio of Targeted Protein Degradation Medicines Phase 1 2 Trial of CFT7455, an IKZF1 3 MonoDAC Degrader, Continues to Progress with Phase 1 Dose
C4 Therapeutics has announced its strategic priorities for 2023, focusing on advancing targeted protein degradation medicines. The company is progressing with Phase 1 trials for multiple candidates, including CFT7455 and CFT8634, with dose escalation data expected in the second half of the year. Additionally, C4T has sufficient funds to support its operations until the end of 2024, positioning itself strongly in the oncology space. The upcoming presentation at the J.P. Morgan Healthcare Conference highlights its commitment to innovation.
Read more →CCCCC4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights The Phase 1 2 Clinical Trials of CFT7455, an IKZF1 3 MonoDAC Degrader, and CFT8634, a BRD9 BiDAC Degrader, Continue to Enroll Pa
C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights The Phase 1 2 Clinical Trials of CFT7455, an IKZF1 3 MonoDAC Degrader, and CFT8634, a BRD9 BiDAC Degrader, Continue to Enroll Patients and Advance Through Dose Escalation IND Clearance A
Read more →CCCC▲ +6.9%on this news
C4 Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights - CFT7455, a Novel IKZF1 3 Degrader, Advancing Through Dose Escalation Portion of Phase 1 2 Clinical Trial - - Phase 1 2 Clinic
C4 Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights - CFT7455, a Novel IKZF1 3 Degrader, Advancing Through Dose Escalation Portion of Phase 1 2 Clinical Trial - - Phase 1 2 Clinical Trial for CFT8634, a BRD9 Degrader, Enrolling Patients
Read more →CCCC▲ +6%on this news· ran to +35% by day 3shared move
C4 Therapeutics Appoints Experienced Clinical Development Leaders Laura Bessen, M.D. and Donna Grogan, M.D. to Board of Directors - Dr. Laura Bessen Brings More Than Two Decades of Experience Across Medical Affairs and C
C4 Therapeutics Appoints Experienced Clinical Development Leaders Laura Bessen, M.D. and Donna Grogan, M.D. to Board of Directors - Dr. Laura Bessen Brings More Than Two Decades of Experience Across Medical Affairs and Clinical Development in Support of Successful Product Launch
Read more →CCCC▼ -6.2%on this news
C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC Degrader for the Treatment of Synovial Sarcoma and SMARCB1-null Tumors
C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC Degrader for the Treatment of Synovial Sarcoma and SMARCB1-null Tumors WATERTOWN, Mass., May 16, 2022 (GLOBE NEWSWIRE) - C4 Therapeutics, Inc. (C4T) (Nasdaq
Read more →CCCCC4 Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights - Data from Ongoing CFT7455 Phase 1/2 Trial Presented at the American Association for Cancer Research (AACR) Annual Meeting; Enr
C4 Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights WATERTOWN, Mass., May 5, 2022 (GLOBE NEWSWIRE) - C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation
Read more →CCCC▼ -50.6%on this news· ran to -65% by day 1
C4 Therapeutics Presents Clinical Data from Cohort A of the Ongoing Phase 1/2 Clinical Trial of CFT7455, a Novel IKZF1/3 Degrader - Single Agent CFT7455 Induces Deep and Durable Degradation of IKZF1/3 and Meaningful Decr
C4 Therapeutics Presents Clinical Data from Cohort A of the Ongoing Phase 1/2 Clinical Trial of CFT7455, a Novel IKZF1/3 Degrader WATERTOWN, Mass., April 8, 2022 -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targ
Read more →CCCC▲ +5.3%on this news
C4 Therapeutics Appoints Utpal Koppikar to Board of Directors - Utpal Koppikar, Veteran Life Sciences Industry Financial Executive, Appointed as Independent Member of the Board of Directors, Chair of Audit Committee and
C4 Therapeutics Appoints Utpal Koppikar to Board of Directors - Utpal Koppikar, Veteran Life Sciences Industry Financial Executive, Appointed as Independent Member of the Board of Directors, Chair of Audit Committee and Member of Organization, Leadership and Compensation Committ
Read more →CCCC▲ +14%on this news
C4 Therapeutics Reports Full Year 2021 Financial Results and Recent Business Highlights - Data from Cohort A of the Ongoing Phase 1/2 Trial of CFT7455, a Novel IKZF1/3 Degrader, Accepted for Presentation at the American
C4 Therapeutics Reports Full Year 2021 Financial Results and Recent Business Highlights - Data from Cohort A of the Ongoing Phase 1/2 Trial of CFT7455, a Novel IKZF1/3 Degrader, Accepted for Presentation at the American Association for Cancer Research (AACR) - Pre-clinical Data
Read more →CCCC▲ +8.5%on this news
C4 Therapeutics Announces 2022 Key Milestones to Advance Targeted Protein Degradation Portfolio - Initial Phase 1 Data for CFT7455, a Novel IKZF1/3 Degrader, Expected in 1H 2022- - IND Clearance Achieved for CFT8634, a D
C4 Therapeutics Announces 2022 Key Milestones to Advance Targeted Protein Degradation Portfolio - Initial Phase 1 Data for CFT7455, a Novel IKZF1/3 Degrader, Expected in 1H 2022- - IND Clearance Achieved for CFT8634, a Degrader Targeting BRD9; On Track to Initiate Phase 1 Trial
Read more →CCCCC4 Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Results - Phase 1/2 study of CFT7455, a Novel IKZF1/3 Degrader, Progressing with Data Expected in 2022; Trial-in-Progress Poster Accepte
C4 Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Results - Phase 1/2 study of CFT7455, a Novel IKZF1/3 Degrader, Progressing with Data Expected in 2022; Trial-in-Progress Poster Accepted for Presentation at 63rd ASH Annual Meeting - - Investig
Read more →CCCCC4 Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results - Dosed First Patient in Phase 1/2 Clinical Trial of CFT7455, a novel IKZF1/3 Degrader, in Hematologic Malignancies; Data Expec
C4 Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results - Dosed First Patient in Phase 1/2 Clinical Trial of CFT7455, a novel IKZF1/3 Degrader, in Hematologic Malignancies; Data Expected in 2022 - - Received Orphan Drug Designation for CFT74
Read more →CCCCC4 Therapeutics Presents Pre-clinical Data on CFT7455, a Novel IKZF1/3 Degrader for the Treatment of Hematologic Malignancies, at the 16 th Annual International Conference on Malignant Lymphoma - CFT7455 Demonstrated Hig
C4 Therapeutics Presents Pre-clinical Data on CFT7455, a Novel IKZF1/3 Degrader for the Treatment of Hematologic Malignancies, at the 16th Annual International Conference on Malignant Lymphoma - CFT7455 Demonstrated High Binding Affinity to Cereblon and Target Selectivity in Non
Read more →CCCCC4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT7455, An Orally Bioavailable MonoDAC for Hematologic Malignancies - CFT7455 is Company's First Program to Advance to Clinic
C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT7455, An Orally Bioavailable MonoDAC for Hematologic Malignancies - CFT7455 is Company's First Program to Advance to Clinic - WATERTOWN, Mass., June 14, 2021 (GLOBE NEWSWIRE) - C4 Therapeuti
Read more →CCCCC4 Therapeutics Presents Pre-clinical Data on CFT8919, A Selective Degrader of EGFR L858R, at Keystone Symposium on Targeted Protein Degradation - CFT8919 Induces Tumor Regression in Pre-clinical Models Resistant to Firs
C4 Therapeutics Presents Pre-clinical Data on CFT8919, A Selective Degrader of EGFR L858R, at Keystone Symposium on Targeted Protein Degradation WATERTOWN, Mass., June 7, 2021 (GLOBE NEWSWIRE) - C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a
Read more →CCCCC4 Therapeutics to Advance CFT8919, A Selective Degrader of EGFR L858R, Into IND-enabling Studies - IND Submission for CFT8919 Anticipated mid-2022; Phase 1/2 Trial Initiation Expected by YE 2022 - - CFT8919 is Potent an
C4 Therapeutics to Advance CFT8919, A Selective Degrader of EGFR L858R, Into IND-enabling Studies WATERTOWN, Mass., May 26, 2021 (GLOBE NEWSWIRE) - C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that sel
Read more →CCCCC4 Therapeutics Appoints Lauren White as Chief Financial Officer
C4 Therapeutics Appoints Lauren White as Chief Financial Officer WATERTOWN, Mass., May 20, 2021 (GLOBE NEWSWIRE) - C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing
Read more →CCCCCondensed Consolidated Balance Sheet Data (in thousands) (unaudited)
C4 Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results - Preclinical Data for CFT7455, a novel IKZF1/3 Degrader, in Non-Hodgkin's Lymphoma Xenograft Models Accepted for Presentation at the International Conference on Malignant Lymphoma (ICML)
Read more →CCCCC4 Therapeutics Reports Recent Business Highlights and Full Year 2020 Financial Results - Phase 1/2 Trial for Lead Candidate CFT7455, a MonoDAC Degrader Targeting IKZF1/3 for the Treatment of Hematologic Malignancies, On
C4 Therapeutics Reports Recent Business Highlights and Full Year 2020 Financial Results - Phase 1/2 Trial for Lead Candidate CFT7455, a MonoDAC Degrader Targeting IKZF1/3 for the Treatment of Hematologic Malignancies, On Track for 1H 2021 Initiation Following FDA Clearance of In
Read more →CCCCForward-looking Statements The following presentation contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such a
Corporate Presentation January 2021 Forward-looking Statements The following presentation contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "belie
Read more →CCCCC4 Therapeutics Announces Key 2021 Milestones to Support Progress Toward Goal of Four Clinical-Stage Programs by Year-End 2022 - Investigational New Drug (IND) Application for Lead Candidate CFT7455, a MonoDAC targeting
C4 Therapeutics Announces Key 2021 Milestones to Support Progress Toward Goal of Four Clinical-Stage Programs by Year-End 2022 - Investigational New Drug (IND) Application for Lead Candidate CFT7455, a MonoDAC targeting IKZF1/3 for the Treatment of Hematologic Malignancies, Unde
Read more →CCCCcccc-ex991_6.pptx.htm Corporate Presentation November 2020 2020 C4 Therapeutics, Inc. Forward-looking Statements and Intellectual Property Forward-looking Statements The following presentation contains forward-looking st
Corporate Presentation November 2020 2020 C4 Therapeutics, Inc. Forward-looking Statements and Intellectual Property Forward-looking Statements The following presentation contains forward-looking statements. All statements other than statements of historical fact are forward-loo
Read more →CCCCC4 Therapeutics Reports Business Highlights and Third Quarter 2020 Financial Results Strengthened leadership team with appointments of Andrew Hirsch as Chief Executive Officer, William McKee as Chief Financial Officer an
C4 Therapeutics Reports Business Highlights and Third Quarter 2020 Financial Results Strengthened leadership team with appointments of Andrew Hirsch as Chief Executive Officer, William McKee as Chief Financial Officer and Jolie M. Siegel as Chief Legal Officer Completed upsiz
Read more →Competitive Position
How CCCC ranks across every disease it competes inCompetitive Position is a premium feature
See how CCCC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial